MedTrace Logo

Supplementation Absorption Comparison

NCT07791797 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-08-28

No results posted yet for this study

Summary

The goal of this interventional study is to compare the absorption of supplements with and without absorption enhancing technology in healthy volunteers. We will be testing vitamin D3 and omega 3 in both males and females 18 years and older. Part A will comprise of two arms receiving a single dose of omega-3 supplement, and two arms who will receive vitamin D3 supplement daily for 7 days. Part B comprises of two arms who will receive vitamin D3 supplement daily for 6 weeks.

Conditions

  • Healthy Volunteer

Interventions

DIETARY_SUPPLEMENT

Aquacelle® Omega 3

Participants will consume 1 capsule containing 315mg EPA and DHA

DIETARY_SUPPLEMENT

Comparator Omega 3

Participants will consume 1 capsule containing 315mg EPA and DHA

DIETARY_SUPPLEMENT

Plexosome® Vitamin D3

Participants will have 1000IU vitamin D3 each day for 7 days

DIETARY_SUPPLEMENT

Comparator Vitamin D3

Participants will have 1000IU vitamin D3 each day for 7 days

DIETARY_SUPPLEMENT

Plexosome® Vitamin D3 6 weeks

Participants will have 1000IU vitamin D3 each day for 6 weeks

COMBINATION_PRODUCT

Comparator Vitamin D3 6 weeks

Participants will have 1000IU vitamin D3 each day for 6 weeks

Sponsors & Collaborators

  • RDC Clinical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • David Briskey · RDC Clinical

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07791797 on ClinicalTrials.gov